Belite Bio, Inc Financials
This page shows Belite Bio, Inc (BLTE) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Belite Bio, Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Belite Bio, Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Belite Bio, Inc reported a net loss of $77.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Belite Bio, Inc reported an operating loss of $84.2M against $2K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Belite Bio, Inc's EBITDA was -$84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 111.0% from the prior year.
Belite Bio, Inc reported -$77.6M in net income in fiscal year 2025. This represents a decrease of 114.7% from the prior year.
Belite Bio, Inc earned -$2.31 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 95.8% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Belite Bio, Inc recorded an outflow of $37.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 26.3% from the prior year.
Belite Bio, Inc held $352.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Belite Bio, Inc's ROE was -10.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 14.7 percentage points from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Belite Bio, Inc invested $45.4M in research and development in fiscal year 2025. This represents an increase of 51.6% from the prior year.
Belite Bio, Inc invested $71K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 38.8% from the prior year.
Not reported for fiscal year 2025.
BLTE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| R&D Expenses | $45.4M+51.6% | $29.9M+20.5% | $24.8M+180.1% | $8.9M+19.5% | $7.4M+101.2% | $3.7M |
| SG&A Expenses | $38.8M+286.1% | $10.1M+47.4% | $6.8M+72.7% | $4.0M+66.2% | $2.4M+15.7% | $2.1M |
| Operating Income | -$84.2M-110.5% | -$40.0M-26.3% | -$31.7M-147.0% | -$12.8M-30.9% | -$9.8M-70.6% | -$5.7M |
| Interest Expense | $2K-90.0% | $20K-20.0% | $25K+56.3% | $16K | N/A | $21K |
| Income Tax | $0-100.0% | $6K-33.3% | $9K | N/A | N/A | $1K |
| Net Income | -$77.6M-114.7% | -$36.1M-14.3% | -$31.6M-150.1% | -$12.6M-30.9% | -$9.7M-68.0% | -$5.8M |
| EPS (Diluted) | -$2.31-95.8% | -$1.18+0.8% | -$1.19-88.9% | -$0.63 | -$1.01-55.4% | -$0.65 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
BLTE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Total Assets | $780.6M+413.1% | $152.1M+60.7% | $94.6M+113.8% | $44.3M+141.3% | $18.3M | N/A |
| Current Assets | $494.3M+236.1% | $147.1M+63.5% | $89.9M+110.1% | $42.8M+145.6% | $17.4M | N/A |
| Cash & Equivalents | $352.9M+1014.2% | $31.7M-64.1% | $88.2M+109.5% | $42.1M+142.7% | $17.3M-32.3% | $25.6M |
| Total Liabilities | $10.1M+59.6% | $6.3M+49.9% | $4.2M+51.9% | $2.8M-91.7% | $33.4M | N/A |
| Current Liabilities | $9.9M+63.3% | $6.0M+66.5% | $3.6M+72.7% | $2.1M+28.7% | $1.6M | N/A |
| Total Equity | $770.5M+428.4% | $145.8M+61.3% | $90.4M+117.9% | $41.5M+375.0% | -$15.1M-114.5% | -$7.0M |
| Retained Earnings | -$185.3M-72.1% | -$107.6M-50.5% | -$71.5M-79.3% | -$39.9M-46.5% | -$27.2M-54.7% | -$17.6M |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BLTE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$37.0M-26.5% | -$29.2M+2.0% | -$29.8M-160.4% | -$11.5M-53.3% | -$7.5M-68.3% | -$4.4M |
| Capital Expenditures | $71K-38.8% | $116K+84.1% | $63K-84.0% | $394K+432.4% | $74K | N/A |
| Free Cash Flow | -$37.1M-26.3% | -$29.4M+1.8% | -$29.9M-152.3% | -$11.9M-57.0% | -$7.5M | N/A |
| Investing Cash Flow | -$305.1M-175.9% | -$110.6M-175411.1% | -$63K+84.0% | -$394K-603.6% | -$56K-180.0% | -$20K |
| Financing Cash Flow | $663.2M+693.4% | $83.6M+10.1% | $76.0M+105.5% | $37.0M+6440.1% | -$583K-102.1% | $28.1M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BLTE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 |
|---|---|---|---|---|---|---|
| Return on Equity | -10.1%+14.7pp | -24.8%+10.2pp | -35.0%-4.5pp | -30.5% | N/A | N/A |
| Return on Assets | -9.9%+13.8pp | -23.8%+9.7pp | -33.4%-4.8pp | -28.6%+24.1pp | -52.7% | N/A |
| Current Ratio | 50.02+25.7x | 24.31-0.4x | 24.76+4.4x | 20.35+9.7x | 10.66 | N/A |
| Debt-to-Equity | 0.010.0x | 0.040.0x | 0.050.0x | 0.07 | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Belite Bio, Inc Ranks
Frequently Asked Questions
Is Belite Bio, Inc profitable?
No, Belite Bio, Inc (BLTE) reported a net income of -$77.6M in fiscal year 2025.
What is Belite Bio, Inc's EBITDA?
Belite Bio, Inc (BLTE) had EBITDA of -$84.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Belite Bio, Inc's return on equity (ROE)?
Belite Bio, Inc (BLTE) has a return on equity of -10.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Belite Bio, Inc's free cash flow?
Belite Bio, Inc (BLTE) recorded an outflow of $37.1M in free cash flow during fiscal year 2025. This represents a -26.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Belite Bio, Inc's operating cash flow?
Belite Bio, Inc (BLTE) recorded an outflow of $37.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Belite Bio, Inc's total assets?
Belite Bio, Inc (BLTE) had $780.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Belite Bio, Inc's capital expenditures?
Belite Bio, Inc (BLTE) invested $71K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Belite Bio, Inc spend on research and development?
Belite Bio, Inc (BLTE) invested $45.4M in research and development during fiscal year 2025.
What is Belite Bio, Inc's current ratio?
Belite Bio, Inc (BLTE) had a current ratio of 50.02 as of fiscal year 2025, which is generally considered healthy.
What is Belite Bio, Inc's debt-to-equity ratio?
Belite Bio, Inc (BLTE) had a debt-to-equity ratio of 0.01 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Belite Bio, Inc's return on assets (ROA)?
Belite Bio, Inc (BLTE) had a return on assets of -9.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Belite Bio, Inc's cash runway?
Based on fiscal year 2025 data, Belite Bio, Inc (BLTE) had $352.9M in cash against an annual operating cash burn of $37.0M. This gives an estimated cash runway of approximately 115 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Belite Bio, Inc's Piotroski F-Score?
Belite Bio, Inc (BLTE) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Belite Bio, Inc's earnings high quality?
Belite Bio, Inc (BLTE) reported a net loss of $77.6M while operations used $37.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Belite Bio, Inc cover its interest payments?
Belite Bio, Inc (BLTE) reported an operating loss of $84.2M against $2K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.